Roche's Fenebrutinib Gets FDA Priority Review For RMS And PPMS

Roche's fenebrutinib has cleared its first formal regulatory gate in the United States, with FDA acceptance of the NDA under Priority Review for both relapsing multiple sclerosis and primary progressive multiple sclerosis, a dual-indication filing with no precedent among BTK inhibitors. For regulatory affairs leads, the acceptance signals that the agency found the submission sufficiently complete to begin substantive review, a threshold that carries weight given the breadth of the clinical package underpinning it.

The NDA rests on three Phase III studies. In FENhance 1 and 2, fenebrutinib reduced annualised relapse rates by 51.1% and 58.5% respectively versus teriflunomide over 96 weeks, with composite confirmed disability progression measures trending in favour of the investigational agent. The FENtrepid PPMS study met its primary endpoint of non-inferiority against Ocrevus (ocrelizumab), the only currently approved therapy for PPMS, with fenebrutinib numerically reducing progression risk by 12% on the cCDP12 measure (HR 0.88; 95% CI: 0.75, 1.03). Separation of curves was observed as early as 24 weeks.

The mechanistic rationale for the dual indication centres on fenebrutinib's non-covalent BTK inhibition and its designed capacity to cross the blood-brain barrier, targeting both peripheral acute inflammation and the chronic CNS inflammation associated with disability accrual. That dual-pathway profile is what distinguishes the submission from prior BTK programmes and is likely to define the agency's review focus, particularly around long-term safety data and CNS exposure characterisation.

From a manufacturing and supply-chain standpoint, a Priority Review designation compresses the standard review clock, which has direct implications for process validation timelines, commercial batch readiness, and any pre-approval inspection scheduling under 21 CFR Part 211. Plant heads and QA directors supporting the fenebrutinib programme will need to align GMP-compliant commercial manufacturing readiness with an accelerated PDUFA date. The oral dosage form also introduces a different scale-up and distribution profile compared with Ocrevus's infusion-based supply chain, a consideration relevant to any contract manufacturing organisations in the network.

If approved, fenebrutinib would become the first high-efficacy oral therapy indicated across both RMS and PPMS, addressing a population of nearly one million Americans living with MS, of whom more than a third currently receive lower-efficacy treatment according to Roche's own figures.

The PDUFA date has not yet been publicly disclosed; that milestone will set the operational clock for pre-approval inspection readiness and label negotiation across both indications.

Source: Roche via GlobeNewswire, 30 September 2026.